Ambit to Use $49M from Series D VC Round to Develop Kinase Inhibitor

Nov 14, 2007

NEW YORK (GenomeWeb News) — Ambit Biosciences has landed $49.3 million in a Series D round of private-equity financing from new and existing investors, the company said today.

Ambit plans to use the funding blast to push its pipeline of small molecule kinase inhibitors, including several drug candidates it has in clinical and pre-clinical development, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Main menu